We are live on ! Find out more

PMV Pharmaceuticals

PMVP

Market cap $75.4M

1.41 USD

0.00

0%

At close Updated Oct 13, 10:49 AM EDT

1 day

0%

5 days

-11.32%

1 month

-3.42%

3 months

10.16%

6 months

4.44%

Year to date

14.63%

1 year

6.82%

5 years

-93.94%

10 years

-96.24%

About: PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Employees: 54

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 50%

Neutral 50%

Negative 0%

Zacks Investment Research

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know

PMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know

PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity

PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by rezatapopt's 46% response rate and 10-month median duration in Y220C-mutant ovarian cancer. PMVP's medicinal chemistry leverages the Y220C mutation to stabilize p53, translating into consistent clinical activity across heavily pretreated patients. Risks include a limited initial market, acquired resistance, significant dilution from recent financings, and pivotal Phase 2 data due in Q4 2026.

PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity

Zacks Investment Research

Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?

PMV Pharmaceuticals, Inc. (PMVP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PMVP's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, and (ii) accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock for each share of common stock or pre-funded warrant sold. The accompanying warrants have an initial exercise price of $1.21 per share, subject to adjustment following a specified regulatory milestone, are immediately exercisable from the date of issuance and will expire five years from the date of issuance.

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PMV Pharma Announces Proposed Public Offering of Securities

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by PMV Pharma. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

PMV Pharma Announces Proposed Public Offering of Securities

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multicenter, single-arm, registrational Phase 2 trial is assessing rezatapopt as monotherapy at a dose of 2000 mg once-daily in patients with TP53 Y220C advanced solid tumors.

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

Zacks Investment Research

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

Zacks Investment Research

PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why

PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why

Zacks Investment Research

PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

See News Rankings

Price charts implemented using Lightweight Charts™